Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.595739 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.595739 33117408!7561359!33117408     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 595739 Nephropedia Template TP {{tp|p=33117408|t=2020. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 |pdf=|usr=}}{{33117408}} gab.com Text The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33117408 #FOAvip Type I interferons (IFN-I) were first discovered over 60 years ago in a classical experiment by Isaacs and Lindenman, who showed that IFN-Is possess antiviral activity. Later, it became one of the first approved protein drugs using heterologous protein expression systems, which allowed its large-scale production. It has been approved, and widely used in a pleiotropy of diseases, including multiple-sclerosis, hepatitis B and C, and some forms of cancer. Preliminary clinical data has supported its effectiveness against potential pandemic pathogens such as Ebola and SARS. Still, more efficient and specific drugs have taken its place in treating such diseases. The COVID-19 global pandemic has again lifted the status of IFN-Is to become one of the more promising drug candidates, with initial clinical trials showing promising results in reducing the severity and duration of the disease. Although SARS-CoV-2 inhibits the production of IFNbeta and thus obstructs the innate immune response to this virus, it is sensitive to the antiviral activity of externally administrated IFN-Is. In this review I discuss the diverse modes of biological actions of IFN-Is and how these are related to biophysical parameters of IFN-I-receptor interaction and cell-type specificity in light of the large variety of binding affinities of the different IFN-I subtypes towards the common interferon receptor. Furthermore, I discuss how these may guide the optimized use IFN-Is in combatting COVID-19. Twit Text FOAVip The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33117408 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33117408 #FOAvip English Wikipedia <ref>{{Cite pmid|33117408}}</ref> The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 #MMPMID33117408 Schreiber G Front Immunol 2020[]; 11 (ä): 595739 PMID33117408show ga Type I interferons (IFN-I) were first discovered over 60 years ago in a classical experiment by Isaacs and Lindenman, who showed that IFN-Is possess antiviral activity. Later, it became one of the first approved protein drugs using heterologous protein expression systems, which allowed its large-scale production. It has been approved, and widely used in a pleiotropy of diseases, including multiple-sclerosis, hepatitis B and C, and some forms of cancer. Preliminary clinical data has supported its effectiveness against potential pandemic pathogens such as Ebola and SARS. Still, more efficient and specific drugs have taken its place in treating such diseases. The COVID-19 global pandemic has again lifted the status of IFN-Is to become one of the more promising drug candidates, with initial clinical trials showing promising results in reducing the severity and duration of the disease. Although SARS-CoV-2 inhibits the production of IFNbeta and thus obstructs the innate immune response to this virus, it is sensitive to the antiviral activity of externally administrated IFN-Is. In this review I discuss the diverse modes of biological actions of IFN-Is and how these are related to biophysical parameters of IFN-I-receptor interaction and cell-type specificity in light of the large variety of binding affinities of the different IFN-I subtypes towards the common interferon receptor. Furthermore, I discuss how these may guide the optimized use IFN-Is in combatting COVID-19. |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy/pathology[MESH] |Cytokine Release Syndrome/drug therapy[MESH] |Humans[MESH] |Immunity, Innate/drug effects[MESH] |Interferon Type I/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology[MESH] |SARS-CoV-2[MESH] |Signal Transduction/immunology[MESH]The Role of Type I Interferons in the Pathogenesis and Treatment of CO(epmc).pdf DeepDyve Pubget Overpricing